Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says

Amy Jackson, Japan Representative, PhRMA If Japan moves to inappropriately use its version of cost-effective assessments (CEAs) for drug re-pricing, it could end up giving lower prices for medicines that are more effective and innovative than older products, demotivating companies...read more